[Clinical and hemodynamic tolerance of intravenous XXXX in the acute phase of @entity583 ].

@entity1 @entity1009 @entity713 @entity3988 @entity9054 @entity583
The aim of this paper is to study the clinical and haemodynamic tolerance of intravenous @entity3988 in a bolus dose of 10 mg followed by an infusion of 360 mg over 24 hours in 12 @entity1 in the acute phase of @entity583 . We did not observe any significant modification in the heart rate or in the pulmonary artery diastolic pressure. The mean blood pressure decreased from 111.5 +/- 11.8 mmHg to 92.8 +/- 12.7 mmHg (p less than 0.001) after a 24 infusion. The cardiac index increased from 2.34 +/- 0.62 1 X @entity1009 X m-2 to 3.05 +/- 0.95 1 X min-1 X m-2 (p less than 0.05) and the systemic vascular resistance decreased from 2 150 +/- 640 dyn. s.cm-5 to 1 403 +/- 308 dyn.s.cm-5 (p +/- 0.005). Three @entity1 presented a rise in the pulmonary artery diastolic pressure of more than 30 mmHg and in one of these @entity1 , the @entity3988 had to be stopped. These three @entity1 all had a high initial pulmonary capillary pressure (greater than 18 mmHg). The drug was well tolerated clinically. On electrocardiography, four @entity1 presented @entity9054 , all of which regressed when the @entity3988 was stopped (a 3rd degree @entity713 with narrow QRS complexes, a Luciani-Wenckebach type of 2nd degree @entity713 and two cases of 1st degree @entity713 . Overall, intravenous @entity3988 was well tolerated in terms of clinical and haemodynamic parameters in these @entity1 in the acute phase of a @entity583 , provided the left ventricular filling pressure was not excessively elevated.(ABSTRACT TRUNCATED AT 250 WORDS)
